Ligand Pharmaceuticals Incorporated (LGND)Healthcare | Biotechnology | Jupiter, United States | NasdaqGM
280.49 USD
-4.03
(-1.416%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 280.49 |
Hot Take ↕ | Aug. 22, 2026, 3:11 a.m. EDT
Ligand Pharmaceuticals presents a compelling long-term growth story backed by exceptional profitability and revenue expansion, yet the short-term path remains complicated by technical resistance and insider caution. The company maintains a fortress-like balance sheet with cash exceeding debt and generates robust returns on equity, fueling a strong buy recommendation from analysts who see significant upside potential. However, the stock is currently trading below its fifty-day moving average, indicating a short-term cooling off after a broader rally. While the underlying business quality is outstanding, the lack of a dividend and recent insider selling create friction for immediate investors. Speculators are betting on a recovery toward $330 while protecting against a drop to $260, reflecting a cautious optimism that aligns with the solid fundamentals but acknowledges the volatility inherent in the biotechnology sector. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.031045 |
| AutoETS | 0.031045 |
| MSTL | 0.033069 |
| AutoTheta | 0.056823 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 0.33 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.355 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2010-07-01 |
| Last Dividend Date | 2007-04-02 |
| Debt to Equity Ratio | 116.944 |
| Revenue per Share | 14.752 |
| Market Cap | 5,591,738,368 |
| Trailing P/E | 29.28 |
| Forward P/E | 23.50 |
| Beta | 0.98 |
| Profit Margins | 67.88% |
| Website | https://www.ligand.com |
As of Aug. 22, 2026, 3:11 a.m. EDT: Speculators are positioning for upside moves beyond $330 with significant out-of-the-money call open interest, while hedging downside risks near $260 with substantial put open interest. Implied volatility is elevated at deep strikes, suggesting uncertainty around major price thresholds.
| Date | Dividend | Yield % |
|---|---|---|
| 2007-04-03 | 9.357455 | 33.068783 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.73773897 |
| Address1 | 555 Heritage Drive |
| Address2 | Suite 200 |
| All Time High | 326.63 |
| All Time Low | 4.11728 |
| Ask | 396.53 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 182,230 |
| Average Daily Volume3 Month | 360,633 |
| Average Volume | 360,633 |
| Average Volume10Days | 182,230 |
| Beta | 0.983 |
| Bid | 216.6 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 48.57 |
| City | Jupiter |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 280.49 |
| Current Ratio | 31.178 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 283.995 |
| Day Low | 277.36 |
| Debt To Equity | 116.944 |
| Earnings Call Timestamp End | 1,786,019,400 |
| Earnings Call Timestamp Start | 1,786,019,400 |
| Earnings Growth | 8.25 |
| Earnings Quarterly Growth | 9.008 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | 133,011,000 |
| Ebitda Margins | 0.4578 |
| Enterprise To Ebitda | 40.338 |
| Enterprise To Revenue | 18.467 |
| Enterprise Value | 5,365,433,856 |
| Eps Current Year | 9.31514 |
| Eps Forward | 11.93494 |
| Eps Trailing Twelve Months | 9.58 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,278,028,800 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 296.5102 |
| Fifty Day Average Change | -16.020203 |
| Fifty Day Average Change Percent | -0.05402918 |
| Fifty Two Week Change Percent | 73.773895 |
| Fifty Two Week High | 326.63 |
| Fifty Two Week High Change | -46.140015 |
| Fifty Two Week High Change Percent | -0.1412608 |
| Fifty Two Week Low | 160.8 |
| Fifty Two Week Low Change | 119.68999 |
| Fifty Two Week Low Change Percent | 0.7443407 |
| Fifty Two Week Range | 160.8 - 326.63 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 722,097,000,000 |
| Float Shares | 19,478,286 |
| Forward Eps | 11.93494 |
| Forward P E | 23.501583 |
| Free Cashflow | 139,748,880 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 47 |
| Fullday Change | -4.03 |
| Fullday Change Percent | -1.41642 |
| Fullday Price | 280.49 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.81198996 |
| Gross Profits | 235,916,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02375 |
| Held Percent Institutions | 1.1601 |
| Implied Shares Outstanding | 19,935,609 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investor.ligand.com/Investors/Investor-Overview/default.aspx |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,175,558,400 |
| Last Dividend Value | 9.357455 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,667,347,200 |
| Last Split Factor | 1,603:1000 |
| Long Business Summary | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. |
| Long Name | Ligand Pharmaceuticals Incorporated |
| Market | us_market |
| Market Cap | 5,591,738,368 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_30820 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 197,220,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,672,079,472 |
| Number Of Analyst Opinions | 11 |
| Open | 283.7 |
| Operating Cashflow | 131,714,000 |
| Operating Margins | 0.13488 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.53 |
| Phone | 858 550 7500 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 280.49 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 284.52 |
| Price Eps Current Year | 30.111195 |
| Price Hint | 2 |
| Price To Book | 5.774964 |
| Price To Sales Trailing12 Months | 19.245886 |
| Profit Margins | 0.6788 |
| Quick Ratio | 30.826 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | -4.03 |
| Regular Market Change Percent | -1.41642 |
| Regular Market Day High | 283.995 |
| Regular Market Day Low | 277.36 |
| Regular Market Day Range | 277.36 - 283.995 |
| Regular Market Open | 283.7 |
| Regular Market Previous Close | 284.52 |
| Regular Market Price | 280.49 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 127,695 |
| Return On Assets | 0.039920002 |
| Return On Equity | 0.21962 |
| Revenue Growth | 0.337 |
| Revenue Per Share | 14.752 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 19,935,609 |
| Shares Percent Shares Out | 0.1228 |
| Shares Short | 2,448,076 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,918,207 |
| Short Name | Ligand Pharmaceuticals Incorpor |
| Short Percent Of Float | 0.1472 |
| Short Ratio | 8.03 |
| Source Interval | 15 |
| State | FL |
| Symbol | LGND |
| Target High Price | 390.0 |
| Target Low Price | 247.0 |
| Target Mean Price | 342.81818 |
| Target Median Price | 345.0 |
| Total Cash | 1,357,757,952 |
| Total Cash Per Share | 68.107 |
| Total Debt | 1,131,453,056 |
| Total Revenue | 290,542,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 9.58 |
| Trailing P E | 29.278706 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 229.97266 |
| Two Hundred Day Average Change | 50.517334 |
| Two Hundred Day Average Change Percent | 0.2196667 |
| Type Disp | Equity |
| Volume | 127,695 |
| Website | https://www.ligand.com |
| Zip | 33,458 |